Sandoz Group (OTCMKTS:SDZNY) Sees Large Volume Increase – Should You Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) saw unusually-strong trading volume on Wednesday . Approximately 65,426 shares changed hands during mid-day trading, an increase of 112% from the previous session’s volume of 30,842 shares.The stock last traded at $83.78 and had previously closed at $82.65.

Analyst Ratings Changes

A number of equities analysts recently weighed in on SDZNY shares. The Goldman Sachs Group upgraded shares of Sandoz Group to a “strong-buy” rating in a research report on Wednesday, April 1st. Royal Bank Of Canada lowered shares of Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, March 23rd. Barclays upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 12th. Three research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Sandoz Group Stock Performance

The company has a current ratio of 1.18, a quick ratio of 0.77 and a debt-to-equity ratio of 0.53. The firm’s 50-day moving average price is $81.45 and its two-hundred day moving average price is $78.02.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.